AMNEAL PHARMACEUTICALS, INC. Increase (Decrease) in Inventories
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Increase (Decrease) in Inventories of $124.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $69.19M, a 203.79% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $54.96M, a 314.38% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $20.18M, a 61.18% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $30.81M, a 28.52% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2025 was $87.03M, a 33.33% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2024 was $130.53M, a 3.45% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2023 was $126.18M, a 23.23% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2022 was $102.40M, a 108.91% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month | Increase (Decrease) in Inventories 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $69.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $124.15M 10-Q · filed 2026-08-06 | $144.33M derived: sum of 3 quarters · filed 2026-08-06 | $175.14M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $54.96M 10-Q · filed 2026-05-07 | $75.14M derived: sum of 2 quarters · filed 2026-05-07 | $105.95M derived: sum of 3 quarters · filed 2026-05-07 | $128.72M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $20.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $50.99M derived: sum of 2 quarters · filed 2026-02-27 | $73.76M derived: sum of 3 quarters · filed 2026-08-06 | $87.03M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $30.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $53.58M derived: sum of 2 quarters · filed 2026-08-06 | $66.85M 10-Q · filed 2025-11-06 | $118.83M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $22.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $36.04M 10-Q · filed 2026-08-06 | $88.02M derived: sum of 3 quarters · filed 2026-08-06 | $131.12M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $13.26M 10-Q · filed 2026-05-07 | $65.25M derived: sum of 2 quarters · filed 2026-05-07 | $108.35M derived: sum of 3 quarters · filed 2026-05-07 | $131.59M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $51.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $95.08M derived: sum of 2 quarters · filed 2026-02-27 | $118.33M derived: sum of 3 quarters · filed 2026-02-27 | $130.53M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $43.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $66.34M derived: sum of 2 quarters · filed 2025-11-06 | $78.55M 10-Q · filed 2025-11-06 | $101.64M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $23.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $35.45M 10-Q · filed 2025-08-07 | $58.54M derived: sum of 3 quarters · filed 2026-02-27 | $101.10M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $12.20M 10-Q · filed 2025-05-07 | $35.29M derived: sum of 2 quarters · filed 2026-02-27 | $77.86M derived: sum of 3 quarters · filed 2026-02-27 | $115.87M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | $23.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $65.66M derived: sum of 2 quarters · filed 2026-02-27 | $103.67M derived: sum of 3 quarters · filed 2026-02-27 | $126.18M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $42.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $80.58M derived: sum of 2 quarters · filed 2024-11-12 | $103.09M 10-Q · filed 2024-11-12 | $114.16M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-06-30 | $38.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $60.53M 10-Q · filed 2024-08-09 | $71.60M derived: sum of 3 quarters · filed 2025-02-28 | $97.53M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2023-03-31 | $22.51M 10-Q · filed 2024-05-08 | $33.58M derived: sum of 2 quarters · filed 2025-02-28 | $59.51M derived: sum of 3 quarters · filed 2025-02-28 | $99.36M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $11.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $37.00M derived: sum of 2 quarters · filed 2025-02-28 | $76.85M derived: sum of 3 quarters · filed 2025-02-28 | $102.40M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $25.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $65.78M derived: sum of 2 quarters · filed 2023-11-09 | $91.33M 10-Q · filed 2023-11-09 | $74.70M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $39.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $65.39M 10-Q · filed 2023-08-08 | $48.77M derived: sum of 3 quarters · filed 2024-03-14 | $59.83M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $25.55M 10-Q · filed 2023-05-09 | $8.92M derived: sum of 2 quarters · filed 2024-03-14 | $19.98M derived: sum of 3 quarters · filed 2024-03-14 | $54.28M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | -$16.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$5.57M derived: sum of 2 quarters · filed 2024-03-14 | $28.73M derived: sum of 3 quarters · filed 2024-03-14 | $49.02M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $11.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $45.36M derived: sum of 2 quarters · filed 2022-11-07 | $65.64M 10-Q · filed 2022-11-07 | $98.70M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-06-30 | $34.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $54.58M 10-Q · filed 2022-08-08 | $87.64M derived: sum of 3 quarters · filed 2023-03-03 | $135.18M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-03-31 | $20.28M 10-Q · filed 2022-05-06 | $53.34M derived: sum of 2 quarters · filed 2023-03-03 | $100.88M derived: sum of 3 quarters · filed 2023-03-03 | $131.29M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2020-12-31 | $33.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $80.60M derived: sum of 2 quarters · filed 2023-03-03 | $111.00M derived: sum of 3 quarters · filed 2023-03-03 | $113.78M 10-K · filed 2023-03-03 | |
| 2020-09-30 | $47.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $77.94M derived: sum of 2 quarters · filed 2021-11-08 | $80.72M 10-Q · filed 2021-11-08 | $75.21M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $30.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $33.18M 10-Q · filed 2021-08-09 | $27.67M derived: sum of 3 quarters · filed 2022-03-01 | $33.92M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $2.78M 10-Q · filed 2021-05-07 | -$2.73M derived: sum of 2 quarters · filed 2022-03-01 | $3.51M derived: sum of 3 quarters · filed 2022-03-01 | $8.99M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | -$5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $735.00K derived: sum of 2 quarters · filed 2022-03-01 | $6.21M derived: sum of 3 quarters · filed 2022-03-01 | $20.39M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $6.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $11.73M derived: sum of 2 quarters · filed 2020-11-06 | $25.91M 10-Q · filed 2020-11-06 | $14.22M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $5.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $19.66M 10-Q · filed 2020-08-06 | $7.97M derived: sum of 3 quarters · filed 2021-03-01 | -$9.98M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $14.18M 10-Q · filed 2020-05-11 | $2.49M derived: sum of 2 quarters · filed 2021-03-01 | -$15.45M derived: sum of 3 quarters · filed 2021-03-01 | $8.61M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | -$11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$29.63M derived: sum of 2 quarters · filed 2021-03-01 | -$5.57M derived: sum of 3 quarters · filed 2021-03-01 | $42.02M 10-K · filed 2021-03-01 | $42.88M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$17.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $6.12M derived: sum of 2 quarters · filed 2019-11-07 | $53.71M 10-Q · filed 2019-11-07 | $60.35M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-06-30 | $24.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $71.66M 10-Q · filed 2019-08-05 | $78.30M derived: sum of 3 quarters · filed 2020-03-02 | $92.59M derived: sum of 4 quarters · filed 2020-03-02 | |
| 2018-03-31 | $47.59M 10-Q · filed 2019-05-09 | $54.23M derived: sum of 2 quarters · filed 2020-03-02 | $68.53M derived: sum of 3 quarters · filed 2020-03-02 | ||
| 2017-12-31 | $6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $20.94M derived: sum of 2 quarters · filed 2020-03-02 | $31.83M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | $14.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $25.19M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $10.89M 10-Q · filed 2018-08-09 | ||||
| 2016-12-31 | $42.59M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |